BLA 761105 · Abbvie INC
Skyrizi
Risankizumab-Rzaa · Injection · Interleukin-23 Antagonist
NovelOrphanLast checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Apr 23, 2019
Approved uses
12
Original approval plus efficacy supplements
Registered trials
89
36 Phase 3, 18 recruiting
FAERS reports
86,264
57,158 serious, 3,115 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 23, 2026.
SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 ) 1.1 Plaque Psoriasis SKYRIZI ® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older. 1.3 Crohn’s Disease SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults. 1.4 Ulcerative Colitis SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.
Mechanism: Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Risankizumab-rzaa inhibits the release of pro-inflammatory cytokines and chemokines.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 23, 2026 Supplement 53 · Efficacy · priority review OrphanLetterLabelMedication Guide
- Jun 26, 2026 Supplement 45 · Efficacy OrphanLetterLabel
- Jun 12, 2026 Supplement 44 · Efficacy OrphanLetterLabelMedication Guide
- Mar 6, 2026 Supplement 42 · Efficacy OrphanLetterLabel
- Sep 3, 2025 Supplement 39 · Efficacy OrphanLetterLabelMedication Guide
- Jun 18, 2024 Supplement 29 · Efficacy OrphanLetterLabel
- Sep 23, 2022 Supplement 18 · Efficacy OrphanLetterLabel
- Jun 16, 2022 Supplement 16 · Efficacy · priority review OrphanLetterLabel
- Jan 21, 2022 Supplement 14 · Efficacy LetterLabelReview
- Apr 26, 2021 Supplement 9 · Efficacy LetterLabelReview
- Apr 26, 2021 Supplement 10 · Efficacy LetterLabelReview
- Apr 23, 2019 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
2 products under this application
- SKYRIZI · RISANKIZUMAB-RZAA 150MG/ML · INJECTABLE, INJECTION · Prescription
- SKYRIZI · RISANKIZUMAB-RZAA 75MG/0.83ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Risankizumab" as an intervention, any sponsor and status, largest first.
- A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03047395 · 2,170 participants · Start Feb 27, 2017 · Primary completion Nov 29, 2023
Drug: risankizumab · For: Psoriasis
Sites: Birmingham, Alabama; Rogers, Arkansas; Bakersfield, California · 233 sites in all
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07697456 · 2,000 participants (planned) · Start Jul 31, 2026 · Primary completion Oct 2031
Drug: Risankizumab; Trosunilimab and 1 more · For: Crohn's Disease; Ulcerative Colitis
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 66 sites in all
- A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03398148 · 1,558 participants · Start Mar 7, 2018 · Primary completion Nov 9, 2022
Drug: risankizumab IV; placebo for risankizumab and 1 more · For: Ulcerative Colitis (UC)
Sites: Coronado, California; Irvine, California; La Jolla, California · 430 sites in all
- A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's DiseasePivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03105102 · 1,336 participants · Start Apr 9, 2018 · Primary completion Feb 2029
Drug: Placebo for Risankizumab SC; Risankizumab IV and 3 more · For: Crohn's Disease
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 496 sites in all
- A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative ColitisPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03398135 · 1,242 participants · Start Aug 28, 2018 · Primary completion Sep 2028
Drug: risankizumab; placebo for risankizumab · For: Ulcerative Colitis (UC)
Sites: Coronado, California; Irvine, California; La Jolla, California · 426 sites in all
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) TherapyPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03675308 · 964 participants · Start Mar 25, 2019 · Primary completion Oct 8, 2020
Drug: Placebo; Risankizumab · For: Psoriatic Arthritis
Sites: Anniston, Alabama; Peoria, Arizona; Phoenix, Arizona · 256 sites in all
- A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03105128 · 931 participants · Start May 10, 2017 · Primary completion Nov 9, 2020
Drug: placebo for risankizumab; risankizumab IV and 1 more · For: Crohn's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tempe, Arizona · 475 sites in all
- BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02694523 · 684 participants · Start Mar 2016 · Primary completion Aug 2017
Drug: risankizumab; adalimumab and 2 more · For: Psoriasis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- psoriasis8,117
- drug ineffective3,773
- pain3,387
- fatigue3,279
- arthralgia3,261
- device issue2,933
- pruritus2,798
- death2,379
- surgery2,376
- fall2,347
- covid-192,283
- crohn^s disease2,240
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 357 |
| 2020 | 1,931 |
| 2021 | 4,103 |
| 2022 | 16,392 |
| 2023 | 15,176 |
| 2024 | 14,507 |
| 2025 | 19,572 |
| 2026 | 14,223 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Skyrizi* (Risankizumab-Rzaa)
2024 spending
$316M
Beneficiaries
5,557
16,641 claims
Per beneficiary
$56,792
$17,021.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $76,341,484 |
| 2022 | $251,093,665 |
| 2023 | $289,245,101 |
| 2024 | $315,590,528 |
Part B: Skyrizi* (Risankizumab-Rzaa*) · HCPCS J2327
2024 spending
$76.7M
Beneficiaries
3,490
8,485 claims
Per beneficiary
$21,983
2024 ASP limit $15.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $41,263,286 |
| 2024 | $76,720,174 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, et al. · JAMA 2024 · Clinical Trial, Phase III, Multicenter Study
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. · N Engl J Med 2024 · Multicenter Study, Randomized Controlled Trial
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology 2024 · Systematic Review, Comparative Study
- Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, et al. · Lancet 2022 · Randomized Controlled Trial
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S, Murad MH, Fumery M, et al. · Lancet Gastroenterol Hepatol 2021 · Comparative Study, Research Support, N.I.H., Extramural
- Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
Barberio B, Gracie DJ, Black CJ, et al. · Gut 2023 · Systematic Review, Network Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.